国产达沙替尼与伊马替尼一线治疗接受造血干细胞移植的Ph染色体阳性急性淋巴细胞白血病患者的疗效比较
该回顾性研究纳入2014年1月至2017年6月期间接受造血干细胞移植的63例初诊Ph(+)ALL患者,比较一线应用国产达沙替尼(31例)与伊马替尼(32例)的疗效。两组诱导4周CR率、MMR率、移植前复发率及移植前MMR率差异均无统计学意义;20个月OS率差异无统计学意义,但20个月EFS率差异有统计学意义,国产达沙替尼组更优。多因素分析显示应用国产达沙替尼和移植前获得MMR与更好的EFS相关。
要点
- 国产达沙替尼组与伊马替尼组20个月EFS率分别为93.5%和61.4%,差异有统计学意义(χ²=5.926,P=0.015)。
- 两组20个月OS率分别为95.5%和76.5%,差异无统计学意义(χ²=0.990,P=0.320)。
- 多因素分析显示应用国产达沙替尼(HR=0.201,95%CI 0.045~0.896,P=0.035)和移植前获得MMR(HR=0.344,95%CI 0.124~0.956,P=0.041)与更好的EFS相关。
核心结论
- 与一线应用伊马替尼相比,一线应用国产达沙替尼可改善接受造血干细胞移植的Ph(+)ALL患者的EFS。
研究设计与样本
- 回顾性分析2014年1月至2017年6月期间就诊并行造血干细胞移植的63例初诊Ph(+)ALL患者的临床特征及转归。
- 应用国产达沙替尼者31例,应用伊马替尼者32例。
主要发现
- 两组诱导治疗4周CR率分别为96.8%和93.8%(P=1.000)。
- 两组诱导治疗4周MMR率分别为41.9%和43.8%(χ²=0.021,P=0.884)。
- 两组移植前复发率分别为6.5%和12.5%(P=0.672),移植前MMR率分别为83.9%和68.8%(χ²=1.985,P=0.159),差异均无统计学意义。
- 国产达沙替尼组和伊马替尼组20个月OS率分别为95.5%和76.5%,差异无统计学意义(χ²=0.990,P=0.320);20个月EFS率分别为93.5%和61.4%,差异有统计学意义(χ²=5.926,P=0.015)。
- 多因素分析显示应用国产达沙替尼(HR=0.201,95%CI 0.045~0.896,P=0.035)和移植前获得MMR(HR=0.344,95%CI 0.124~0.956,P=0.041)的患者具有更好的EFS。
临床怎么用
- TKI联合化疗并序贯造血干细胞移植治疗Ph(+)ALL时,与一线应用伊马替尼相比,一线应用国产达沙替尼者EFS更优。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy of first-line administration of generic dasatinib or first-generation TKI (imatinib) in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph(+) ALL) treated by hematopoietic stem cell transplantation (HSCT). Methods: Clinical features and prognoses of 63 newly diagnosed Ph(+) ALL patients from Jan 2014 to June 2017 treated by HSCT combined with first-line administration of generic dasatinib or imatinib were retrospective analyzed. Results: Of 63 Ph(+) ALL patients, 31 cases were administered generic dasatinib, and the other 32 ones imatinib. Complete remission (CR) rates at the fourth week of induction therapy in generic dasatinib and imatinib groups were 96.8% and 93.8% (P=1.000) , respectively. Meanwhile major molecular response (MMR; BCR-ABL/ABL reduce 3log) rates were 41.9% and 43.8% (χ(2)=0.021, P=0.884), respectively. Relapse rates before transplantation were 6.5% and 12.5% (P=0.672), respectively. MMR rates before HSCT were 83.9% and 68.8% (χ(2)=1.985, P=0.159), respectively. The 20-monthes overall survival (OS) rates of generic dasatinib and imatinib groups were 95.5% and 76.5% (χ(2)=0.990, P=0.320) respectively; 20-monthes event-free survival (EFS) rates were 93.5% and 61.4% (χ(2)=5.926, P=0.015), respectively. Statistically significant differences of EFS were reached. Multiple factors analysis showed that generic dasatinib (HR=0.201, 95% CI 0.045-0.896, P=0.035) and MMR before transplantation (HR=0.344, 95% CI 0.124-0.956, CI=0.041) could improve EFS. Conclusions: First-line administration of generic dasatinib could improve EFS for Ph(+)ALL patients treated by HSCT when compered with imatinib. 目的: 探讨接受造血干细胞移植的Ph染色体阳性急性淋巴细胞白血病(Ph(+)ALL)患者一线应用国产达沙替尼与一代酪氨酸激酶抑制剂(TKI)伊马替尼的疗效差异。 方法: 回顾性分析2014年1月至2017年6月期间就诊并行造血干细胞移植的63例Ph(+)ALL患者的临床特征及转归,比较一线应用国产达沙替尼与伊马替尼的疗效。 结果: 应用国产达沙替尼者31例,应用伊马替尼者32例。两组患者诱导治疗4周完全缓解(CR)率分别为96.8%和93.8%(P=1.000),诱导治疗4周主要分子学反应(MMR,BCR-ABL拷贝数较基线下降3个对数级)率分别为41.9%和43.8%(χ(2)=0.021,P=0.884),移植前复发率分别为6.5%和12.5%(P=0.672),移植前MMR率分别为83.9%和68.8%(χ(2)=1.985,P=0.159),差异均无统计学意义。国产达沙替尼组和伊马替尼组20个月总生存(OS)率分别为95.5%、76.5%,20个月无事件生存(EFS)率分别为93.5%、61.4%,两组OS时间差异无统计学意义(χ(2)=0.990,P=0.320),EFS时间差异有统计学意义(χ(2)=5.926,P=0.015)。多因素分析显示应用国产达沙替尼(HR=0.201,95% CI 0.045~0.896,P=0.035)和移植前获得MMR(HR=0.344,95% CI 0.124~0.956,P=0.041)的患者具有更好的EFS。 结论: TKI联合化疗并序贯造血干细胞移植治疗Ph(+)ALL时,与一线应用伊马替尼相比,一线应用国产达沙替尼者EFS更优。.
引用
- Yang F, Cai WZ, Huang XW, et al. [Comparison of efficacy of first-line administration of generic dasatinib or imatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia treated by hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30180468. doi:10.3760/cma.j.issn.0253-2727.2018.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。